List of Excipients in Branded Drug AKOVAZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Exela Pharma Sciences LLC	AKOVAZ	ephedrine sulfate	51754-4200	ACETIC ACID
Exela Pharma Sciences LLC	AKOVAZ	ephedrine sulfate	51754-4200	SODIUM HYDROXIDE
Exela Pharma Sciences LLC	AKOVAZ	ephedrine sulfate	51754-4200	WATER

AKOVAZ Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

AKOVAZ is a concentrated phenylephrine hydrochloride injection, USP, used to treat clinically significant hypotension caused by vasodilation, including during anesthesia. Its commercial value is driven less by active-ingredient differentiation than by sterile manufacturing reliability, excipient compatibility, ready-to-use presentation, shortage resilience, and hospital purchasing economics. The strongest opportunities are preservative-free presentations, lower-concentration ready-to-administer products, premixed infusion bags, and supply-chain alternatives for anesthesia and critical-care markets.

What is AKOVAZ and how is it formulated?

AKOVAZ contains phenylephrine hydrochloride at 10 mg/mL in a sterile injectable solution. The product is supplied in a single-dose vial and must be diluted before intravenous administration according to the prescribing information.[1]

The labeled inactive ingredients are:

Excipient	Functional role	Commercial or technical relevance
Sodium chloride	Tonicity adjustment	Supports physiologic osmolality and injection tolerability
Sodium citrate dihydrate	Buffering agent	Controls pH and supports chemical stability
Citric acid monohydrate	Acidifying and buffering agent	Works with citrate to maintain the acidic formulation range
Sodium metabisulfite	Antioxidant	Limits oxidative degradation of phenylephrine
Water for Injection	Vehicle	Sterile solvent for parenteral administration

The formulation is acidic, with a labeled pH range of approximately 3.5 to 5.5. Sodium metabisulfite is a material safety consideration because sulfite sensitivity can cause serious reactions in susceptible patients.[1]

AKOVAZ is a high-concentration product. A 10 mg/mL vial is efficient for storage and shipment but creates a dilution and dosing burden at the point of care. That tradeoff creates the central commercial opening for alternative presentations.

What excipient functions are most important in AKOVAZ?

Chemical stability

Phenylephrine is susceptible to oxidative degradation. The inclusion of sodium metabisulfite indicates that oxidation control is a core formulation requirement. Oxygen exposure, light, container closure performance, headspace composition, metal-ion contamination, and terminal sterilization conditions should be assessed together rather than optimized independently.

A competing product could seek a sulfite-free formulation through oxygen-control measures, antioxidant substitution, lower oxygen headspace, improved container closure integrity, or an alternative manufacturing process. That approach would require a comparative stability package and careful evaluation of degradation products.

A sulfite-free strategy has potential clinical and commercial value, but it is not automatically superior. Removing sodium metabisulfite may increase formulation complexity, packaging cost, or sensitivity to manufacturing variability.

pH control

The citrate and citric acid system maintains the product in an acidic range. Buffer capacity must be sufficient to control pH during manufacture and storage without creating excessive local acidity after dilution.

A reformulated product should evaluate:

• Initial pH and pH drift over shelf life
• Buffer capacity after dilution
• Compatibility with common infusion solutions
• Precipitation or visible-particle formation
• Adsorption to infusion bags and administration sets
• Stability after dilution under refrigerated and room-temperature conditions

A lower-buffer formulation may improve dilution behavior, but it could reduce long-term stability. A higher-buffer formulation may improve pH control while increasing the risk of incompatibility with certain diluents or co-administered drugs.

Tonicity

Sodium chloride provides tonicity adjustment in the concentrated vial. After dilution, tonicity is determined by the final preparation and the selected diluent. A ready-to-use product would require a separate tonicity strategy because the final concentration, administration route, and infusion volume would differ from the current concentrated vial.

For direct syringe administration, the formulation should be assessed for injection volume, osmolality, local tolerability, and compatibility with commonly used syringe materials. For infusion bags, the formulation must remain stable in the selected diluent and container over the labeled in-use period.

Sulfite exposure

Sodium metabisulfite is a potential differentiator in product development. A competitor could position a sulfite-free phenylephrine injection for institutions seeking to reduce excipient-related adverse-event concerns.

The commercial claim would need to remain precise. Sulfite removal does not eliminate the active ingredient's cardiovascular risks, including hypertension, bradycardia, and extravasation injury. The value proposition is narrower: removing a known excipient sensitivity concern while maintaining chemical stability.

What formulations are protected or commercially differentiated?

The principal formulation opportunities are presentation-based rather than dependent on a new active ingredient.

Product concept	Primary excipient issue	Hospital value	Development burden
Current 10 mg/mL single-dose vial	Oxidation control and dilution	Low acquisition cost; flexible dosing	Established benchmark
Lower-concentration ready-to-use syringe	Tonicity, pH, syringe compatibility	Reduces bedside preparation and calculation errors	Moderate
Premixed infusion bag	Diluent compatibility and in-use stability	Reduces compounding workload	Moderate to high
Sulfite-free vial	Alternative oxidation strategy	Addresses sulfite sensitivity concerns	High stability burden
Preservative-free syringe	Container closure and microbial controls	Supports anesthesia and emergency use	Moderate
Dual-chamber or dilution-ready system	Separation of unstable components	Extends stability before use	High device and regulatory burden
Pharmacy bulk package	Sterility and repeated withdrawal controls	Supports institutional compounding	High compliance burden

AKOVAZ is already a single-dose injectable presentation. The commercial distinction between a preservative-free product and the current product should therefore be handled carefully. The stronger opportunity is a ready-to-administer system that reduces manipulation, rather than a generic "preservative-free" claim alone.

When does AKOVAZ lose exclusivity?

AKOVAZ is a small-molecule phenylephrine hydrochloride product, so biosimilar exclusivity is not relevant. The competitive framework is generic-drug approval under section 505(j) of the Federal Food, Drug, and Cosmetic Act, including possible Paragraph IV challenges where applicable.

Public product information identifies AKOVAZ as a phenylephrine hydrochloride injection approved by FDA. FDA labeling and approval records should be used to confirm the current application holder, marketing status, and any listed patents or exclusivity.[1][2]

The commercial exclusivity analysis has four parts:

1. FDA approval and any remaining regulatory exclusivity.
2. Orange Book-listed patents, if any.
3. Paragraph IV certifications and associated litigation.
4. Manufacturing and supply barriers that may delay practical competition.

For an older injectable active ingredient such as phenylephrine, regulatory exclusivity is generally less important than sterile manufacturing capacity, drug-shortage conditions, purchasing contracts, and the ability to obtain reliable supply. A listed patent can delay a generic launch, but an absence of listed patents does not guarantee immediate competition.

What is the Orange Book status of AKOVAZ?

The Orange Book is the relevant source for patents and therapeutic-equivalence information for approved small-molecule drug products.[2] The Orange Book status must be evaluated at the application level because patent listings, delistings, and marketing status can change.

For AKOVAZ, the key diligence questions are:

• Whether the product is listed as an active prescription drug product.
• Whether FDA has listed any patent information for the application.
• Whether an authorized generic or therapeutically equivalent product is available.
• Whether any exclusivity code remains active.
• Whether the application holder continues commercial distribution.

No biosimilar pathway applies. A competing phenylephrine injection would typically pursue an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA's product-specific requirements.

Formulation and device improvements may be patentable even where the basic phenylephrine product is not. Potential claim areas include:

• Sulfite-free injectable compositions
• Specific citrate-buffer and pH ranges
• Oxygen-controlled packaging
• Stable diluted solutions
• Ready-to-use syringes
• Premixed infusion bags
• Container closure systems
• Manufacturing methods that reduce oxidative impurities

A patent directed only to routine excipient substitution may face substantial validity and obviousness scrutiny. Stronger protection would require demonstrated stability, compatibility, usability, or clinical advantages linked to defined formulation parameters.

Which companies are challenging AKOVAZ?

The relevant competitors are manufacturers of phenylephrine hydrochloride injection rather than companies developing biosimilars. The competitive set can include branded products, authorized generics, ANDA-approved injections, outsourcing facilities, and compounded preparations.

FDA's Drugs@FDA database, the Orange Book, and the FDA drug-shortage database are the primary sources for identifying approved competitors and current supply conditions.[2][3] ASHP's shortage database is also relevant for hospital procurement analysis.[4]

Competition is likely to develop through:

• Lower-cost generic vials
• Alternative vial sizes
• Ready-to-use syringes
• Premixed bags
• Contract-manufactured sterile injectables
• Hospital pharmacy compounding
• Products designed for anesthesia carts and emergency departments

The most credible commercial threat to a concentrated vial is not necessarily another concentrated vial. A ready-to-use syringe can win on labor reduction, dosing standardization, and medication-safety protocols even at a higher unit price.

What generic entry risks exist for AKOVAZ?

Generic entry risk is moderate to high at the active-ingredient level but lower at the practical supply level if sterile capacity remains constrained.

High-risk factors

• Phenylephrine is an established small molecule.
• The injection route and active ingredient are well characterized.
• Hospital demand is recurring.
• Alternative sterile injectable manufacturers can pursue ANDA approval.
• Formulation complexity is manageable relative to biologics or complex delivery systems.

Factors that can delay competition

• Limited sterile fill-finish capacity
• Container closure qualification
• Extractables and leachables testing
• Stability failures related to oxidation
• Drug-shortage remediation requirements
• FDA inspection findings
• Difficulty securing reliable raw materials
• Contracting barriers with group purchasing organizations

A generic entrant with a basic vial may face price pressure. An entrant with differentiated packaging or a ready-to-use format may obtain better margins and greater formulary access.

How does AKOVAZ compare with ready-to-use phenylephrine products?

Attribute	AKOVAZ concentrated vial	Ready-to-use syringe	Premixed infusion bag
Preparation burden	Requires dilution	Minimal	Minimal
Storage efficiency	High	Lower	Low
Dosing error risk	Higher during dilution	Lower	Lower
Hospital labor cost	Higher	Lower	Lower
Formulation complexity	Established	Moderate	High
Packaging cost	Low to moderate	Moderate to high	High
Differentiation potential	Limited	High	High
Likely purchasing rationale	Unit price and flexibility	Safety and speed	Workflow and continuous infusion

Ready-to-use products can justify a premium if hospitals quantify reductions in pharmacy preparation, nursing time, medication errors, and discarded doses. The commercial case is strongest in operating rooms, emergency departments, intensive-care units, and ambulatory surgical centers.

What FDA regulatory pathway applies to an AKOVAZ competitor?

A conventional phenylephrine injection competitor would generally pursue an ANDA under section 505(j). A materially different formulation, delivery system, or presentation may require a 505(b)(2) application, depending on the degree of difference and the reference product used.

Regulatory development should address:

• Active ingredient identity and strength
• Sterility and endotoxin control
• Particulate matter
• Extractables and leachables
• Container closure integrity
• Stability and photostability
• Dilution compatibility
• In-use stability
• Preservative or antioxidant content
• Labeling of sulfite sensitivity
• Administration instructions
• Drug-drug and container compatibility

A ready-to-use syringe may trigger combination-product or device-related considerations if the delivery system is integral to the intended use. Human-factors validation may become important where the product is designed to replace bedside dilution.

What licensing and partnering opportunities exist?

The most attractive partnering models involve sterile injectable platforms rather than licensing phenylephrine itself.

Potential structures include:

• Licensing a ready-to-use syringe technology to a generic manufacturer
• Co-development with a contract development and manufacturing organization
• Acquiring a 505(b)(2) formulation platform
• Supplying a differentiated product to a hospital-focused distributor
• Entering a regional commercialization agreement for premixed bags
• Using a contract manufacturer with validated oxygen-control and aseptic-fill capabilities

A formulation owner would have more leverage if it can demonstrate a measurable hospital economic benefit. Useful evidence includes reduced preparation time, fewer compounding steps, lower waste, longer in-use stability, and compatibility with automated medication-dispensing systems.

What revenue exposure does AKOVAZ represent?

AKOVAZ-specific revenue is difficult to isolate from public company reporting because phenylephrine products are generally reported within broader injectable or hospital-product portfolios. The relevant market variables are:

• Annual procedure volume
• Emergency and critical-care demand
• Hospital contract duration
• Generic price erosion
• Product availability during shortages
• Mix between vials, syringes, and bags
• Wholesale acquisition cost
• Group purchasing organization discounts

A concentrated vial usually competes on acquisition price. A ready-to-use product competes on total cost of use. The latter includes pharmacy labor, nursing time, waste, medication-error exposure, storage, and inventory management.

A differentiated product can therefore maintain pricing above commodity generic levels if it has reliable availability and a validated workflow benefit.

How strong is the patent estate for AKOVAZ?

The underlying phenylephrine molecule is old, and broad composition-of-matter protection is not expected to provide meaningful exclusivity. The likely patent strength of the AKOVAZ product depends on later-filed claims covering formulation, packaging, delivery, or manufacturing.

A strong patent position would require:

• Narrow but reproducible formulation ranges
• Unexpected stability or impurity results
• Clear performance advantages over known phenylephrine injections
• Claims tied to a specific container or delivery system
• Supporting comparative data
• Claims that are difficult to design around economically

A weak estate would consist of broad claims covering routine buffers, ordinary tonicity agents, or predictable antioxidant substitutions without comparative evidence.

Commercial protection may therefore come more from FDA approval timing, manufacturing know-how, validated suppliers, customer contracts, and shortage-era purchasing relationships than from basic formulation patents.

Key Takeaways

• AKOVAZ is a concentrated 10 mg/mL phenylephrine hydrochloride injection.
• Its excipient system uses sodium chloride, citrate and citric acid buffering, sodium metabisulfite, and Water for Injection.
• Oxidation control is the main formulation challenge.
• A sulfite-free formulation is commercially interesting but requires a credible replacement stability strategy.
• The strongest product opportunity is a ready-to-use syringe or premixed infusion presentation.
• Biosimilar risk does not apply because phenylephrine is a small molecule.
• Generic entry risk is substantial at the active-ingredient level, but sterile manufacturing and supply reliability can delay practical competition.
• Formulation patents are more likely to protect differentiated presentations than the basic drug.
• The value of a new product should be measured by total hospital cost, not vial price alone.
• FDA, Orange Book, Drugs@FDA, and shortage databases should anchor current regulatory and competitive diligence.

FAQs

Is AKOVAZ preservative-free?

AKOVAZ is labeled as a single-dose injectable product and contains sodium metabisulfite as an antioxidant. Sodium metabisulfite should be treated as an excipient sensitivity consideration rather than a conventional antimicrobial preservative.[1]

Can AKOVAZ be sold as a ready-to-use syringe?

A ready-to-use syringe would be a materially differentiated presentation requiring formulation, container, stability, labeling, and potentially device-related development. The regulatory pathway would depend on the specific formulation and delivery system.

Does AKOVAZ have biologic or biosimilar competition?

No. AKOVAZ contains phenylephrine hydrochloride, a synthetic small-molecule active ingredient. Competition would generally come from generic injectable products, 505(b)(2) products, and compounded preparations.

What excipient could replace sodium metabisulfite in AKOVAZ?

No replacement can be selected solely from the label. Candidate strategies may include alternative antioxidants, oxygen-controlled packaging, nitrogen headspace, chelation, or process controls. Each approach requires comparative stability and impurity data.

What is the best commercial format for a new phenylephrine product?

A ready-to-use syringe is the strongest differentiation opportunity where hospitals value rapid administration, standardized dosing, and reduced bedside preparation. Premixed bags may be more attractive for continuous infusion protocols, while concentrated vials remain competitive where acquisition price and storage efficiency dominate.

References

1. U.S. Food and Drug Administration. (n.d.). AKOVAZ (phenylephrine hydrochloride) injection, solution: Prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). FDA drug shortages database. FDA Center for Drug Evaluation and Research.

4. American Society of Health-System Pharmacists. (n.d.). Drug shortages resource center: Phenylephrine injection. ASHP.